#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Castleman's disease Oesophageal squamous cell carcinoma stage II Adenocarcinoma gastric Deafness bilateral Follicular lymphoma stage II Endometrial cancer Follicular lymphoma Anti-myelin-associated glycoprotein antibodies positive Brain stem glioma Pustular psoriasis Thymic carcinoma Haemophilia B with anti factor IX Scedosporium infection Cytomegalovirus infection Non-small cell lung cancer recurrent More trials…

    Learn about Rare Diseases

    X-linked lymphoproliferative syndrome – Life with Disease Primary mediastinal large B-cell lymphoma – Trials in Disease Primary hyperoxaluria – Trials in Disease Synovial sarcoma metastatic – Trials in Disease Malignant fibrous histiocytoma – Basic Information Angiosarcoma non-metastatic – Diagnostics Factor VIII deficiency Glycogen storage disease type I – Life with Disease Atypical teratoid/rhabdoid tumour of CNS Sarcoidosis – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    VOXVOGANAN Cipaglucosidase Alfa SGN-ALPV Givinostat Efgartigimod Alfa Tovorafenib Bdc-1001 Highly Refined Fish Oil Ale.c04 Lapatinib VANDETANIB AGANIRSEN GSKVX000000048111 Eletriptan Rasagiline Lisinopril Dihydrate Pbf-999 Csm-Gw ACARBOSE Maralixibat Chloride More therapies…

    Learn about Your Condition

    Alexander disease Retroperitoneal fibrosis Post procedural infection Retroperitoneal cancer Retinopathy proliferative Retinopathy of prematurity Breast angiosarcoma Medication overuse headache Indolent systemic mastocytosis Connective tissue disorder Rosai-Dorfman syndrome Monogenic diabetes Death neonatal Transient ischaemic attack Hypertriglyceridaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Mantle cell lymphoma

  • Phase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients

    Recruiting

    3 1 1
    Investigated Drugs:
    • Bendamustine Hydrochloride
    • Rituximab
    Czechia France Poland Romania Spain

  • Study of glofitamab, obinutuzumab and tocilizumab in patients with mantle cell lymphoma relapsed or refractory after CAR‑T therapy

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Glofitamab
    • Obinutuzumab
    • Tocilizumab
    Italy

  • A study to evaluate the effectiveness of pirtobrutinib in elderly and frail patients with mantle cell lymphoma who have not yet received treatment.

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Mantle cell lymphoma
    Investigated Drugs:
    • Pirtobrutinib
    Italy

  • Study of Glofitamab and Pirtobrutinib Treatment in Patients with Mantle Cell Lymphoma Who Have Failed Previous Therapy and in Previously Untreated Patients

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Mantle cell lymphoma
    Investigated Drugs:
    • Glofitamab
    • Obinutuzumab
    • Pirtobrutinib
    Denmark Germany Norway Spain Sweden

  • Study on the Effectiveness and Safety of Pirtobrutinib and Rituximab for Untreated Adult Patients with Indolent Mantle Cell Lymphoma

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Pirtobrutinib
    • Rituximab
    Portugal Spain

  • Study of Acalabrutinib with R-CHOP for Patients with Untreated Mantle Cell Lymphoma in Spain

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Mantle cell lymphoma
    Investigated Drugs:
    • Acalabrutinib
    Spain
1 2 3 … 5
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!